← Back to Screener
Lite Strategy, Inc. Common Stock (LITS)
Price$1.19
Favorite Metrics
Price vs S&P 500 (26W)-60.97%
Price vs S&P 500 (4W)-8.64%
Market Capitalization$42.54M
All Metrics
Book Value / Share (Quarterly)$2.23
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.33
Price vs S&P 500 (YTD)-14.74%
Gross Margin (TTM)100.00%
Net Profit Margin (TTM)39.05%
EPS (TTM)$-2.39
10-Day Avg Trading Volume0.19M
EPS Excl Extra (TTM)$-2.39
EPS (Annual)$-2.39
Dividend / Share (Annual)$0.00
ROI (Annual)-94.18%
Gross Margin (Annual)100.00%
Net Profit Margin (5Y Avg)-92.08%
Cash / Share (Quarterly)$0.24
ROA (Last FY)-87.20%
EBITD / Share (TTM)$-2.49
ROE (5Y Avg)-71.43%
Operating Margin (TTM)34.86%
Cash Flow / Share (Annual)$-3.13
P/B Ratio0.52x
P/B Ratio (Quarterly)0.59x
Net Income / Employee (Annual)$-4
Net Interest Coverage (TTM)-21.51x
ROA (TTM)-69.93%
EPS Incl Extra (Annual)$-2.39
Current Ratio (Annual)13.50x
Quick Ratio (Quarterly)8.06x
3-Month Avg Trading Volume0.44M
52-Week Price Return-39.49%
Revenue / Employee (TTM)$0
P/S Ratio (Annual)0.65x
Asset Turnover (Annual)1.58x
52-Week High$9.00
Operating Margin (5Y Avg)-100.94%
EPS Excl Extra (Annual)$-2.39
26-Week Price Return-52.23%
Quick Ratio (Annual)13.30x
13-Week Price Return-23.87%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)10.04x
Enterprise Value$33.786
Asset Turnover (TTM)0.84x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)27.23%
Cash / Share (Annual)$2.70
3-Month Return Std Dev68.90%
Gross Margin (5Y Avg)38.18%
Net Income / Employee (TTM)$-4
ROE (Last FY)-94.18%
EPS Basic Excl Extra (Annual)$-2.39
P/FCF (TTM)0.58x
Receivables Turnover (TTM)1306.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.39
Receivables Turnover (Annual)1305.94x
ROI (TTM)-76.43%
P/S Ratio (TTM)0.40x
Pretax Margin (5Y Avg)-92.08%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-74.58%
Year-to-Date Return-10.61%
5-Day Price Return3.51%
EPS Normalized (Annual)$-2.39
ROA (5Y Avg)-24.99%
Net Profit Margin (Annual)27.23%
Month-to-Date Return1.72%
EBITD / Share (Annual)$-2.49
Operating Margin (Annual)22.27%
ROI (5Y Avg)-71.43%
EPS Basic Excl Extra (TTM)$-2.39
Payout Ratio (Annual)65.59%
P/B Ratio (Annual)0.97x
Dividend / Share (TTM)$0.00
Pretax Margin (TTM)39.05%
Book Value / Share (Annual)$2.54
Price vs S&P 500 (13W)-26.74%
Dividend Yield (TTM)0.00%
Beta0.14x
P/FCF (Annual)1.27x
Revenue / Share (TTM)$0.00
ROE (TTM)-76.43%
52-Week Low$0.95
Analyst Recommendations
Aug 2025
Sep 2025
Oct 2025
Nov 2025
2.17
2.17
2.17
2.17
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
LITSLite Strategy, Inc. Common Stock | 0.40x | — | 100.00% | — | $1.19 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Lite Strategy Inc is a clinical-stage pharmaceutical company developing novel therapies for cancer. The company's pipeline includes voruciclib, an oral CDK9 inhibitor, and zandelisib, an oral PI3K inhibitor, both designed to improve patient outcomes in oncology.